Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Net Cash Flow (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Net Cash Flow for 2 consecutive years, with -$70.6 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 283.22% to -$70.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$110.2 million through Dec 2025, down 310.07% year-over-year, with the annual reading at -$110.2 million for FY2025, 310.07% down from the prior year.
  • Net Cash Flow hit -$70.6 million in Q4 2025 for Silence Therapeutics, down from $40.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $74.0 million in Q1 2024 to a low of -$70.6 million in Q4 2025.